{"nctId":"NCT00091169","briefTitle":"Levocarnitine in Treating Fatigue in Cancer Patients","startDateStruct":{"date":"2005-12-16","type":"ACTUAL"},"conditions":["Fatigue","Unspecified Adult Solid Tumor, Protocol Specific"],"count":376,"armGroups":[{"label":"Arm I","type":"EXPERIMENTAL","interventionNames":["Dietary Supplement: levocarnitine"]},{"label":"Arm II","type":"PLACEBO_COMPARATOR","interventionNames":["Other: placebo"]}],"interventions":[{"name":"levocarnitine","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of an invasive malignant disorder\n* Moderate to severe fatigue within the past 4 weeks, defined as a score of ≥ 2 (on a scale of 0-4) on the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) question \"I feel fatigued\"\n* Age 18 and over\n* Eastern Cooperative Oncology Group (ECOG) Performance status of 0-3\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for 3 months after study participation\n\nExclusion Criteria:\n\n* Brain metastases\n* Hemoglobin \\< 9 g/dL, taken \\<=4 weeks prior to registration\n* Severe, uncontrolled liver disease\n* Evidence of severely compromised renal function including any 1 of the following:\n\n  * Renal failure\n  * End stage renal disease\n  * Ongoing renal dialysis\n* Severe, uncontrolled cardiovascular disease\n* Severe, uncontrolled pulmonary disease\n* Pregnant or nursing\n* History of seizures\n* Known sensitivity to carnitine\n* Delirium\n* Nausea \\> grade 1\n* Taking any form of levocarnitine (L-carnitine) supplementation or nutritional supplements containing carnitine within 2 months prior to registration","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Score Change in Fatigue Measured With Brief Fatigue Inventory From Baseline to 4 Weeks","description":"Fatigue was measured using Brief Fatigue Inventory (BFI). The average of all 9 items included in the scale (range: 0-10) was used to measure fatigue level, and a higher average represented worse fatigue. Score change= BFI score at 4 weeks - BFI score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.96","spread":null},{"groupId":"OG001","value":"-1.11","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Score Change in Fatigue Measured With FACIT-F From Baseline to 4 Weeks","description":"Fatigue was measured using Functional Assessment of Cancer Therapy- Fatigue subscale (FACIT-F). The sum of the scores for all 13 items (range: 0-52) included in the scale was used to measure fatigue level, and lower score represented worse fatigue. Score change= FACIT-F score at 4 weeks - FACIT-F score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.36","spread":null},{"groupId":"OG001","value":"4.04","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Score Change in Depression Measured With CES-D Between 4 Weeks and Baseline","description":"Depression was measured using Center for Epidemiologic Studies Depression Scale (CES-D). The sum of the scores for all 20 items (range: 0-60) was used to assess depression level, and higher scores indicated a higher level of depression. Score change= CES-D score at 4 weeks - CES-D score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.05","spread":null},{"groupId":"OG001","value":"-2.91","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Score Change in Pain Measured With Brief Pain Inventory From Baseline to 4 Weeks","description":"Pain was measured using Brief Pain Inventory (BPI). The mean of the 4 severity items (range: 0-10 with 0 representing no pain and 10 representing pain as bad as you can imagine) was used to measure pain severity. Score change= BPI score at 4 weeks - BPI score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.19","spread":null},{"groupId":"OG001","value":"-0.08","spread":null}]}]}]},{"type":"SECONDARY","title":"Prevalence of Carnitine Deficiency at 4 Weeks","description":"Carnitine deficiency is defined as a ratio of acylcarnitine (total-free) to free carnitine \\> 0.4 μmol/L or free carnitine \\< 35 μmol/L for males and \\< 25 μmol/L for females.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.113","spread":null},{"groupId":"OG001","value":"0.333","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With Stable or Improving Performance Status at 4 Weeks","description":"Performance status (PS) was measured using Eastern Cooperative Oncology Group performance status scale. Lower score represents better PS. Change in PS was calculated by PS at week 4- PS at baseline. Patients with negative value for change in PS were considered to have stable or improving PS.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.806","spread":null},{"groupId":"OG001","value":"0.875","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":166},"commonTop":["Anemia"]}}}